Morgan Stanley Maintains Equal-Weight on Biogen, Lowers Price Target to $222

Benzinga · 07/08 16:25
Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and lowers the price target from $224 to $222.